BD’s Onclarity HPV Assay: What it means for the future of cervical cancer detection


Pathology expert Mark H. Stoler, MD, discussed the BD Onclarity™ HPV Assay for primary HPV screening and what it means for the future of cervical cancer detection.

Becton, Dickinson and Company's (BD) Onclarity HPV Assay received FDA approval in August 2021, making it the only assay currently approved that individually identifies and reports HPV genotypes 31, 51, 52, 33/58, 35/39/68, and 56/59/66, as well as the standard 16,18, and 45.


Mark H. Stoler, MD, professor of pathology, cytology, and gynecology in the department of cytology, University of Virginia, focuses his research efforts on molecular analysis of gene expression as applied to oncologic pathology.

Disclosures: Stoler is a consultant for BD Diagnostics.

Download the ASCCP Management Guidelines app

Related Videos
Fertility counseling for oncology patients | Image Credit:
Learning what women prefer in STI preventive care
Why doxycycline PEP lacks clinical data for STI prevention in women
The importance of nipocalimab’s FTD against FNAIT | Image Credit:
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit:
New algorithm to identify benign lesions developed | Image Credit:
How fezolinetant changes management of hot flashes | Image Credit:
Anne Banfield, MD | Image Credit: © Medstar
Jonathan Miller, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.